Biosidus is an Argentine biotechnology company engaged in the development, manufacturing, and commercialization of high-quality recombinant proteins and biopharmaceuticals. Since launching Erythropoetin in 1990, the company has successfully marketed a range of biosimilars, including Interferon Alfa 2a, Interferon Alfa 2b, Filgrastim, Somatropin, Lenograstim, Azacitidine, Bortezomib, Interferon beta 1a (SC and IM), and Teriparatide. Today, these products are commercialized in over 50 markets. With headquarters and manufacturing plants located in Buenos Aires, Argentina, Biosidus has developed regional hubs to intensify its presence across Asia, Africa, Eastern Europe, and Latin America.

Services include:
- Anatomical Therapeutic Chemical (ATC) Classification
- Research and Development of Biopharmaceuticals
- Manufacturing and Quality Control
- Marketing and Commercialisation of Biologics
- Regulatory Affairs and Compliance

Biosidus continues to innovate and expand its portfolio within the biopharmaceutical sector, maintaining a commitment to quality and accessibility. For more information, please visit biosidus.com.ar.